PET scan for suspected returning prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new imaging drug, 18F-Florastamin, to see if it can better detect prostate cancer that has come back after treatment. You may qualify if you have signs of recurrence and are willing to have a biopsy or additional therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You were originally diagnosed with prostate adenocarcinoma through a biopsy.
- You had treatment (surgery or radiation) and now have rising PSA levels suggesting the cancer may have returned.
- Your doctor thinks you might need a biopsy, salvage surgery, or more radiation.
- You are in good enough health to walk and care for yourself (ECOG score 0 or 2).
- Your blood counts, kidney, and liver function are within safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of PET scan (a detailed imaging test) to find out if prostate cancer has come back after treatment. You'll receive an injection of a special tracer and then have a scan that takes pictures to help doctors locate any cancer.
This study tests a new imaging drug called Flotufolastat F-18 to find prostate cancer that has returned after treatment. The goal is to see how well and safely it finds the cancer spots, which could help guide next steps.
This study tests whether a newer type of imaging scan (called fluciclovine PET) can find where prostate cancer has come back when an earlier scan (PSMA PET) didn't show clear results. The goal is to help doctors better plan treatment for men whose cancer has returned after surgery or radiation.
This study follows people with prostate cancer whose PSA blood test has risen again after standard treatment. It uses an approved PET scan tracer to look for cancer spread, which may help doctors understand how the disease is progressing.
This trial tests a new PET scan (a type of imaging) called Flotufolastat to see if it can better monitor prostate cancer after you receive focal therapy—a treatment that targets only the cancer area rather than the whole prostate. The goal is to help doctors know if the treatment worked and catch any remaining cancer early.
This Phase 3 trial tests whether a special PET scan using 68Ga-PSMA-11 can detect prostate cancer that has returned after surgery or radiation, measured by rising PSA. If the scan works well, it may help doctors find where the cancer is coming back.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.